For patients diagnosed with stage IV HER2+ BC, surgery was the least common treatment modality (n = 82, 23.2%) compared with RT (n = 213, 60.2%) and systemic therapy (n = 311, 87.9%) (Table 2). Here, ERBB2 is linked to breast cancer.